Will Teladoc Health Shares Ever Near 2021 Levels Again?

Photo of author
Written By Faith Boluwatife

Teladoc Health is currently navigating through a challenging period as the stock trades at all-time lows and the company recently replaced its long-time CEO. The Covid era was expected to significantly boost the telehealth sector, but Teladoc has struggled to maintain growth following the initial surge during the pandemic.

Despite this, there is a bullish investment thesis based on the company’s cheap valuation and potential in emerging markets like weight loss management. However, the stock’s downward trend reflects market skepticism about the company’s turnaround prospects.

Weight Loss Management Opportunity

Credits: DepositPhotos

The excitement surrounding GLP-1 weight loss drugs has introduced a significant new market opportunity in weight loss management. Teladoc Health is well-positioned to capitalize on this with its recent launch of a weight loss management program, complementing its existing focus on diabetes prevention. These efforts aim to improve patient health and control healthcare costs.

Despite these opportunities, Teladoc Health has struggled with its go-to-market strategy and lacks a compelling product story to drive user growth. During the recent Q1 2024 earnings call, the company’s executives and analysts mentioned advertising and sales far more frequently than AI and weight management, highlighting a potential misalignment in priorities.

The recent appointment of Chuck Divita as CEO is a critical factor in Teladoc Health’s future. Divita’s background at GuideWell, a leading health solutions organization, suggests a strong understanding of healthcare but raises questions about his ability to drive product innovation in telehealth.

Chronic Care Program

Teladoc Health’s Chronic Care program saw enrollment grow 9% year-over-year to 1.121 million members, but this number was down 37,000 members sequentially. Despite launching a Weight Management provider-based care program in early 2023, the company hasn’t seen significant growth in chronic care enrollment.

Valuation and Financial Health

Teladoc Health’s stock has plummeted from a high of $300 during the Covid boom in 2021 to below $10. The company now has a market valuation of $1.7 billion, with a cash balance of $1.1 billion, offset by $1.5 billion in convertible debt. Despite this, the company is targeting $2.7 billion in sales for 2024 and forecasts producing upwards of $240 million in free cash flow this year.

Teladoc Health is trading at an EV/Sales ratio below 1x and an EV/EBITDA ratio of 6x, indicating a potential undervaluation. The opportunity for the new CEO is to drive growth through product innovation, which could lead to multiple expansion and significantly increase the stock’s value.


Credits: DepositPhotos

The key takeaway for investors is that Teladoc Health has significant potential in the booming weight loss management market, but this potential can only be realized if management shifts its focus towards product innovation. Currently, Teladoc Health appears more like a telesales company, lacking in product innovation.

The stock is attractive due to its low valuation and potential in telehealth, but the success of this investment hinges on the new CEO’s ability to steer the company towards innovation and growth.

Teladoc Health, Inc. offers a speculative opportunity for investors willing to bet on a turnaround driven by new market opportunities and strategic shifts. The next few quarters will be crucial in determining whether Teladoc can capitalize on its potential or continue to struggle amidst its internal challenges.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.